Skip to main content
Top
Published in: Journal of Cancer Survivorship 3/2016

01-06-2016

The salience of cancer and the “survivor” identity for people who have completed acute cancer treatment: a qualitative study

Authors: Katherine Clegg Smith, Ann C. Klassen, Kisha I. Coa, Susan M. Hannum

Published in: Journal of Cancer Survivorship | Issue 3/2016

Login to get access

Abstract

Purpose

Globally, there are nearly 33 million persons who have survived 5 or more years after a diagnosis of cancer [1]. We explore the salience of cancer in such people’s self-concept as an important element for creating patient-centered care for those living with a cancer history.

Methods

Our data are responses to a free-listing exercise and subsequent qualitative interviews with 53 individuals aged between 45 and 74 who were diagnosed with non-Hodgkin’s lymphoma or breast or prostate cancer at least 3 years prior and had completed acute treatment. Participants lived in the Baltimore-Washington region of the USA.

Results

Cancer was not necessarily salient to participants’ current self-concept, and espousal of a “survivor” identity is complex. We construct a typology of seven contrasting meanings of “survivor” based upon participants’ narratives (factual, beaten, functional, temporary, adversity, passage of time, and lucky or blessed) and present interviewees’ rationales as to why they did or did not adopt a survivorship identity.

Conclusions

We examine the complexity of “survivorship” as an identity and people’s affiliation with it, as well as how this relates to other salient and fluid elements of people’s sense of self within a life course perspective.

Implications for cancer survivors

Understanding how cancer factors into people’s self-concept throughout the life course is important for designing effective, patient-centered programs that acknowledge diverse experiences and expectations and possible changes with the passage of time.
Appendix
Available only for authorised users
Literature
2.
go back to reference Phillips JM, Cohen MZ, Moses G. Breast cancer screening and African American women: fear, fatalism, and silence. Oncol Nurs Forum. 1999;26:561–71.PubMed Phillips JM, Cohen MZ, Moses G. Breast cancer screening and African American women: fear, fatalism, and silence. Oncol Nurs Forum. 1999;26:561–71.PubMed
3.
go back to reference Clarke JN, Everest MM. Cancer in the mass print media: fear, uncertainty and the medical model. Soc Sci Med. 2006;62:2591–600.CrossRefPubMed Clarke JN, Everest MM. Cancer in the mass print media: fear, uncertainty and the medical model. Soc Sci Med. 2006;62:2591–600.CrossRefPubMed
4.
go back to reference Miles A, Voorwinden S, Chapman S, Wardle J. Psychologic predictors of cancer information avoidance among older adults: the role of cancer fear and fatalism. Cancer Epidem Biomar. 2008;17:1872–9.CrossRef Miles A, Voorwinden S, Chapman S, Wardle J. Psychologic predictors of cancer information avoidance among older adults: the role of cancer fear and fatalism. Cancer Epidem Biomar. 2008;17:1872–9.CrossRef
5.
go back to reference Muzzin LJ, Anderson NJ, Figueredo AT, Gudelis SO. The experience of cancer. Soc Sci Med. 1994;38:1201–8.CrossRefPubMed Muzzin LJ, Anderson NJ, Figueredo AT, Gudelis SO. The experience of cancer. Soc Sci Med. 1994;38:1201–8.CrossRefPubMed
6.
go back to reference Else-Quest NM, LoConte NK, Schiller JH, Shibley HJ. Perceived stigma, self-blame, and adjustment among lung, breast and prostate cancer patients. Psychol Health. 2009;24(8):949–64.CrossRefPubMed Else-Quest NM, LoConte NK, Schiller JH, Shibley HJ. Perceived stigma, self-blame, and adjustment among lung, breast and prostate cancer patients. Psychol Health. 2009;24(8):949–64.CrossRefPubMed
7.
go back to reference Bellizzi K, Blank T. Cancer-related identity and positive affect in survivors of prostate cancer. J Cancer Surviv. 2007;1:44–8.CrossRefPubMed Bellizzi K, Blank T. Cancer-related identity and positive affect in survivors of prostate cancer. J Cancer Surviv. 2007;1:44–8.CrossRefPubMed
9.
go back to reference Park CL, Zlateva I, Blank TO. Self-Identity after cancer: “survivor”, “victim”, “patient”, and “person with cancer”. J Gen Intern Med. 2009;24(Suppl2):S430–5.CrossRefPubMed Park CL, Zlateva I, Blank TO. Self-Identity after cancer: “survivor”, “victim”, “patient”, and “person with cancer”. J Gen Intern Med. 2009;24(Suppl2):S430–5.CrossRefPubMed
10.
go back to reference Deimling GT, Bowman KF, Wagner LJ. Cancer survivorship and identity among long-term survivors. Cancer Invest. 2007;25:758–65.CrossRefPubMed Deimling GT, Bowman KF, Wagner LJ. Cancer survivorship and identity among long-term survivors. Cancer Invest. 2007;25:758–65.CrossRefPubMed
11.
go back to reference Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 1985;313(40):270–3.CrossRefPubMed Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med. 1985;313(40):270–3.CrossRefPubMed
13.
go back to reference Chambers SK, Baade P, Meng X, Youl P, Aitken J, Dunn J. Survivor identity after colorectal cancer: antecedents, prevalence and outcomes. Psychooncology. 2011;21:962–9.CrossRefPubMed Chambers SK, Baade P, Meng X, Youl P, Aitken J, Dunn J. Survivor identity after colorectal cancer: antecedents, prevalence and outcomes. Psychooncology. 2011;21:962–9.CrossRefPubMed
14.
go back to reference Khan NF, Harrison S, Rose PW, Ward A, Evans J. Interpretation and acceptance of the term ‘cancer survivor’: a United Kingdom-based qualitative study. Eur J Cancer Care. 2012;21:177–86.CrossRef Khan NF, Harrison S, Rose PW, Ward A, Evans J. Interpretation and acceptance of the term ‘cancer survivor’: a United Kingdom-based qualitative study. Eur J Cancer Care. 2012;21:177–86.CrossRef
15.
go back to reference Kelly KM, Shah N, Shedlosky-Shoemaker R, Porter K, Agnese D. Living post treatment: definitions of those with history and no history of cancer. J Cancer Surviv. 2011;5:158–66.CrossRefPubMed Kelly KM, Shah N, Shedlosky-Shoemaker R, Porter K, Agnese D. Living post treatment: definitions of those with history and no history of cancer. J Cancer Surviv. 2011;5:158–66.CrossRefPubMed
16.
go back to reference Jagielski CH, Hawley ST, Corbin K, Weiss MC, Griggs JJ. Phoenix rising: who considers herself a “survivor” after a diagnosis of breast cancer? J Cancer Surviv. 2012;6:541–457.CrossRef Jagielski CH, Hawley ST, Corbin K, Weiss MC, Griggs JJ. Phoenix rising: who considers herself a “survivor” after a diagnosis of breast cancer? J Cancer Surviv. 2012;6:541–457.CrossRef
17.
go back to reference Morris BA, Lepor SJ, Wilson B, Lieberman MA, Dunn J, Chambers SK. Adopting a survivor identity after cancer in a peer support context. J Cancer Surviv. 2014;8:427–36.CrossRefPubMed Morris BA, Lepor SJ, Wilson B, Lieberman MA, Dunn J, Chambers SK. Adopting a survivor identity after cancer in a peer support context. J Cancer Surviv. 2014;8:427–36.CrossRefPubMed
18.
go back to reference Bell K, Ristovski-Slijepcevic S. Cancer survivorship: why labels matter. J Clin Oncol. 2013;31:409–11.CrossRefPubMed Bell K, Ristovski-Slijepcevic S. Cancer survivorship: why labels matter. J Clin Oncol. 2013;31:409–11.CrossRefPubMed
19.
go back to reference Glaser B. The constant comparative method of qualitative analysis. Soc Probl. 1965;12:436–45.CrossRef Glaser B. The constant comparative method of qualitative analysis. Soc Probl. 1965;12:436–45.CrossRef
Metadata
Title
The salience of cancer and the “survivor” identity for people who have completed acute cancer treatment: a qualitative study
Authors
Katherine Clegg Smith
Ann C. Klassen
Kisha I. Coa
Susan M. Hannum
Publication date
01-06-2016
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 3/2016
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-015-0489-0

Other articles of this Issue 3/2016

Journal of Cancer Survivorship 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine